DXSE:XETRA:XETRA-Xtrackers - Stoxx Europe 600 Health Care Swap UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 226.15

Change

+2.00 (+0.89)%

Market Cap

USD 0.14B

Volume

106.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-28 )

ETFs Containing DXSE:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.86% 73% C 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.86% 73% C 73% C
Trailing 12 Months  
Capital Gain 16.55% 63% D 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.55% 63% D 65% D
Trailing 5 Years  
Capital Gain 63.92% 77% C+ 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.92% 76% C+ 74% C
Average Annual (5 Year Horizon)  
Capital Gain 8.81% 75% C 72% C
Dividend Return 8.81% 74% C 70% C-
Total Return N/A 17% F 21% F
Risk Return Profile  
Volatility (Standard Deviation) 8.60% 65% D 73% C
Risk Adjusted Return 102.45% 99% N/A 99% N/A
Market Capitalization 0.14B 42% F 38% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.